Division of Nephrology and Hypertension, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
S Afr Med J. 2024 Apr 24;114(3b):e1326. doi: 10.7196/SAMJ.2024.v114i3b.1326.
ABO-incompatible kidney transplantation gives patients with chronic kidney disease requiring dialysis and without a blood group-compatible donor an alternative option for a kidney transplant.
To describe our first experiences and outcomes with 3 patients using Glycosorb ABO immunoadsorption (IA) columns in performing ABO-incompatible living-donor kidney transplants. This is the first time this technique has been used in Africa.
As per the protocol, patients needed between 1 and 4 sessions of IA and received rituximab ~ one month before transplantation.
All the patients achieved the target isohaemagglutinin antibody titre of 1:4 pretransplant. Only 1 patient with the highest initial screening titre (1:256) needed IA post-transplant. None of the patients experienced clinical rejection, and all had good graft kidney function at discharge and at the time of writing.
Glycosorb ABO IA is an effective technique in enabling ABO-incompatible living-donor kidney transplants to be performed successfully in a South African setting.
ABO 血型不相容的肾移植为需要透析且没有血型相容供体的慢性肾脏病患者提供了一种替代的肾移植选择。
描述我们在 3 例 ABO 血型不相容活体供肾移植中使用 Glycosorb ABO 免疫吸附（IA）柱的初步经验和结果。这是该技术首次在非洲使用。
根据方案，患者需要进行 1 至 4 次 IA 治疗，并在移植前一个月接受利妥昔单抗治疗。
所有患者在移植前均达到目标的 1:4 同种血凝素抗体效价。只有 1 例初始筛查效价最高（1:256）的患者在移植后需要进行 IA 治疗。没有患者发生临床排斥反应，所有患者在出院时和撰写本文时均具有良好的移植物肾功能。
Glycosorb ABO IA 是一种有效的技术，可成功在南非环境中进行 ABO 血型不相容的活体供肾移植。
